Correlation of plasma miR-21 and miR-93 with radiotherapy and chemotherapy efficacy and prognosis in patients with esophageal squamous cell carcinoma

Table 4 Correlation of clinical parameters and indexes of esophageal squamous cell carcinoma patients with radiotherapy and chemotherapy efficacy, n (%)

Category	n	Effective (n = 91)	Ineffective (n = 37)	χ2	P-value
Gender				0.058	0.810
Male	95	67 (73.63)	28 (75.68)
Female	33	24 (26.37)	9 (24.32)
Age (Yr)				0.404	0.525
≤ 65	54	40 (43.96)	14 (37.84)
> 65	74	51 (56.04)	23 (62.16)
Smoking history				5.733	0.017a
No	52	43 (47.25)	9 (24.32)
Yes	76	48 (52.75)	28 (75.68)
History of alcoholism				0.839	0.360
No	60	45 (49.45)	15 (40.54)
Yes	68	46 (50.55)	22 (59.46)
T stage				11.380	< 0.001b
T2/T3	98	77 (84.62)	21 (56.76)
T4	30	14 (15.38)	16 (43.24)
N stage				4.543	0.033a
N0	34	29 (31.87)	5 (13.51)
N1	94	62 (68.13)	32 (86.49)
M stage				13.900	< 0.001b
M0	100	79 (86.81)	21 (56.76)
M1	28	12 (13.19)	16 (43.24)
Tumor site				0.283	0.868
Upper 1/3 of thoracic part	44	30 (32.97)	14 (37.84)
Middle 1/3 of thoracic part	59	43 (47.25)	16 (43.24)
Lower 1/3 of thoracic part	25	18 (19.78)	7 (18.92)
Pathological differentiation				5.105	0.024a
Moderate/high differentiation	47	39 (42.86)	8 (21.62)
Low differentiation	81	52 (57.14)	29 (78.38)
Tumor length (cm)				0.592	0.442
≤ 5	30	23 (25.27)	7 (18.92)
> 5	98	68 (74.73)	30 (81.08)
MiR-21				14.870	< 0.001b
≤ 5.80	72	61 (67.03)	11 (29.73)
> 5.80	56	30 (32.97)	26 (70.27)
MiR-93				12.590	< 0.001b
≤ 4.71	99	78 (85.71)	21 (56.76)
> 4.71	29	13 (14.29)	16 (43.24)

^aP < 0.05 vs control group;

^bP < 0.01 vs control group.